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A b s t r a c t  
The main objective of present work was to prepare a solid SEDDS for enhancement of oral 
bioavailability of Valsartan, poorly water soluble drug. The solubility of the drug was determined in 
various vehicles. A pseudo ternary phase diagram was constructed to identify the self-micro 
emulsification region. Further, the resultant formulations were investigated for clarity, phase 
separation, globule size, effect of pH and dilutions and freeze-thaw stability. The optimized 
SMEDDS (F4) formulation of Valsartan contained Capmul MCM (Oil), Kolliphor HS 15 (Surfactant) 
and PEG 400 (Co-surfactant). This optimized formulation was converted in to solid SEDDS by 
adding required quantity of Neusilin US2 as adsorbing agent used for in vitro dissolution and 
bioavailability assessment. The oral bioavailability of Valsartan from solid SEDDS was 1.6-fold 
higher compared to that of Valsartan suspension in rats, suggesting a significant increase (p < 0.05) 
in oral bioavailability of Valsartan from solid SEDDS.  
Keywords: Valsartan, solid SEDDS, particle size, neusilin US2 enhanced oral bioavailability.
Introduction 
Oral route has been the major route of drug delivery for the chronic 
treatment of human diseases. However, oral delivery of 50% of the 
drugs is hampered because of the high lipophilicity [1]. In drug 
discovery, about 40% of the new drug candidates display low 
solubility in water, which leads to poor bioavailability, high intra 
subject/inter subject variability and lack of dose proportionality. 
Therefore producing suitable formulations is very important to 
improve the solubility and bioavailability of such drugs [2]. Self-
emulsifying systems are a useful means of improving the 
bioavailability of poorly water soluble drugs, particularly the self-
micro emulsifying drug delivery systems are well known for their 
potential as alternative strategies for delivery of hydrophobic drugs 
[3]. SEDDS are isotropic mixtures of drug, oil/lipid, surfactant 
and/or co-surfactant, which form fine emulsion/lipid droplets on 
dilution with physiological fluid. The researchers now focused on 
solid SEDDS area were increasing. Solid SEDDS prepared by 
solidification of liquid or semisolid self emulsifying ingredients into 
powders, have gained popularity. These solid SEDDS were 
prepared by extrusion/spheronization method or wet granulation in 
a high shear mixer and adsorption to solid carriers involves 
addition of the liquid formulation onto carriers by mixing in a 
blender [4].  
Hypertension is one of the most prevalent chronic adult illnesses 
today and cannot be cured, but can be controlled. The 
pharmacological treatment for control of hypertension utilizes 
various drug therapies such as single doses or associations of 
diuretics, beta-blockers, calcium channel blockers, angiotensin 
converting enzyme (ACE) inhibitors and angiotensin II receptor 
(AT1) antagonist (ARA) [5]. Valsartan is chemically 3-methyl-2-
[pentanoyl-[[4-[2-(2H-tetrazoyl-5- yl) phenyl] phenyl] methyl] amino] 
butanoic acid is an orally active specific angiotensin II receptor 
blocker effective in lowering blood pressure in hypertensive patient. 
The aim of the present study is to formulate and evaluate a stable 
self micro emulsion and solid SEDDS of poorly water-soluble drug 
Valsartan to enhance the solubility and oral bioavailability.  
Materials and methods 
Materials 
Valzaar 40mg conventional tablets were purchased from Torrent 
pharmaceuticals, Ahmadabad, India. Valsartan was generous gift 
from Hetero drugs limited, Hyderabad, India. Capmul MCM, 
Vitamin E TPGS, Capryol 90, Gelucire 44/14 and Castor oil were 
obtained from Granules India limited, Hyderabad. Lauroglycol, 
Captex 355 and Labrasol were obtained from Aurobindo Pharma 
limited, Hyderabad. Kolliphor RH 40 and Kolliphor HS 15 were 
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Solubility studies 
The solubility of Valsartan in various oils (Capmul MCM, Capryol 
90, Castor oil, Captex 355 and Vitamin E TPGS), surfactants 
(Kolliphor HS 15, Kolliphor RH 40, Gelucire 44/14, labrasol, 
Lauroglycol) and co-surfactants (PEG 400 & 600, Propylene glycol) 
were determined by mixing excess amount of Valsartan with 2 ml 
of each of the individual components. The drug was added to a 5-
ml capacity stoppered glass vial and mixed for 10 min with each 
component using a vortex mixer. The mixture vials were then kept 
at 37 μ 1.0C in an isothermal shaker for 72 h until homogeneity. 
The homogenate samples were then centrifuged at 10,000 RPM 
for 20 min at 4 0C. The supernatant was removed by pipetting and 
the drug concentration was determined by UV-VIS 
spectrophotometer at 250 nm [6].  
Construction of ternary phase diagram 
Pseudo ternary phase diagram is used to map the optimal 
composition range for three key excipients according to the 
resulting droplet size following self emulsification, stability upon 
dilution and viscosity [7]. On the basis of the solubility studies of 
drug in oil, surfactants and co-surfactants were used for 
construction of phase diagram. Surfactant and co-surfactant (Smix) 
in each group were mixed in different weight ratio (1:1, 1:2, 2:1, 
3:1). These Smix ratios are chosen in increasing concentration of 
surfactant with respect to co-surfactant and in increasing 
concentration of co-surfactant with respect to surfactant for detail 
study of the phase diagram for formulation of microemulsion. For 
each phase diagram, oil and specific Smix ratios are mixed 
thoroughly in different weight ratio from 1:9 to 9:1 (1:9, 2:8, 3:7, 
4:6, 5:5, 6:4,7:3, 8:2, 9:1) in different glass vials. Pseudo-ternary 
phase diagram was developed using aqueous titration method. 
Slow titration with aqueous phase is done to each weight ratio of oil 
and Smix and visual observation is carried out for transparent and 
easily flowable o/w micro emulsion. The physical state of the micro 
emulsion was marked on a pseudo-three-component phase 
diagram with one axis representing oil, the other representing 
surfactant and the third representing co-surfactant at fixed weight 
ratios [8].  
Transmittance 
% Transmittance of Valsartan SEDDS was measured by U.V 
spectroscopy at wavelength of 400 to 500nm. A graph for %particle 
range vs. formulations was plotted [9]. 
Emulsification time 
A predetermined volume of mixture (0.2 ml) was added to 300 ml 
of water in a glass beaker and temperature was maintained at 
370C using a magnetic stirrer. The tendency of formation of 
emulsion was observed. If the droplet spreads easily in water was 
judged as ÂgoodÊ and judged as ÂbadÊ  when there was milky or no 
emulsion or  presence of oil droplets [10].  
Development of SEDDS formulations 
Weigh accurately 40mg of Valsartan and transferred in to a glass 
vial. To this Capmul MCM oil was added and warmed on water 
bath. To this oily mixture, Kolliphor HS 15 (surfactant) and Poly 
ethylene glycol 400 (Co-surfactant) mixtures was added. Then the 
components were mixed by gentle stirring and vortex mixing at 37 
ÀC until Valsartan was completely dissolved. Then the mixture was 
sealed in glass vial and stored at room temperature until used [11]. 
The composition was given in the Table 1. 
 
























1:9 F1 40 0.02 0.135 0.045
1:7 F2 40 0.025 0.131 0.043
1:6 F3 40 0.028 0.128 0.042
1:5 F4 40 0.033 0.124 0.041




1:9 F6 40 0.02 0.12 0.06
1:8 F7 40 0.022 0.118 0.059
1:7 F8 40 0.025 0.116 0.058
1:6 F9 40 0.028 0.114 0.057
 









Freeze thawing was employed to evaluate the stability of 
formulations. The formulations were subjected to 3 to 4 freeze-
thaw cycles, which included freezing at ă 4 ĈC for 24 hours followed 
by thawing at 40 ĈC for 24 hours. Centrifugation was performed at 
3000 rpm for 5 minutes. The formulations were then observed for 
phase separation. Only formulations that were stable to phase 
separation were selected for further studies [12]. 
Determination of drug content  
Accurately measured dose of Valsartan formulation (0.2ml) 
equivalent to 40mg was taken in volumetric flask and the volume is 
made to 100ml with phosphate buffer pH 6.8. Suitable dilutions 
were made and absorbance was measured at λmax 250 nm against 
blank by UV-VIS spectroscopy.  
                                  Actual amount of drug in SEDDS 
% Drug content = -------------------------------------------------------   X 100 
                                  Theoretical amount of drug in SEDDS 
 
In Vitro dissolution studies of SEDDS 
The dissolution test was performed using USP type 2 dissolution 
apparatus (paddle method) with 900 ml of pH 6.8 phosphate buffer 
containing various concentrations of Valsartan at 37 0C with a 
paddle speed of 50 rpm. The liquid SEDDS containing 40 mg of 
Valsartan was filled into hard gelatine capsules (Capsule No. 00), 
samples were collected at appropriate time intervals 2, 5, 10, 15, 
20, 25, 30, 45 & 60min. 5 ml of the sample was withdrawn and 
replaced with same volume of dissolution medium and the 
concentration of Valsartan was measured at 250nm by UV-VIS 
spectroscopy [13]. 
Oil adsorption study 
Microcrystalline cellulose, colloidal silicon dioxide, Neusilin US2, 
dicalcium phosphate and tricalcium phosphate were used as 
adsorbents. They were added separately to the optimized liquid 
SEDDS formulation i.e F4 under stirring. Neusilin US2 showed 
higher oil adsorption capacity when compared to microcrystalline 
cellulose and colloidal silicon dioxide (shown in the figure 23) [14].  
Conversion of SEDDS to solid SEDDS 
The optimized liquid SEDDS formulation (F4) based on droplet size 
and dissolution study was converted into free flowing powder by 
adsorption onto solid carriers. The composition was shown in Table 
2. The solid carrier used for adsorption comprised of materials that 
provided a high surface area with good disintegration 
characteristics. 200 mg of Neusilin US2 (Magnesium aluminum 
silicate) was used as a solid carrier. It can adsorb at high levels up 
to 70% (w/w). The conversion process involved addition of liquid 
formulation onto carriers under continuous mixing. The powder was 
dried and filled directly into capsules [15]. 
 
 
Table 2: Composition of Valsartan SEDDS and solid SEDDS 
S. No     Components (%wt/wt)          F4
Liquid SEDDS (mg) 
Solid SEDDS(mg) 
1            Valsartan          40           40 
2            Capmul MCM          52.78           52.78 
3            Kolliphor HS 15          205           205 
4            PEG-400          71.41           71.41 
5            Neusilin US2            -           200 
 
Determination of drug content of solid SEDDS 
Accurately weighed dose of Valsartan solid SEDDS was taken in 
volumetric flask and make the volume upto 100ml with phosphate 
buffer pH 6.8. Suitable dilutions were made and absorbance was 
measured at λmax 250 nm against blank. The amount of drug 
present in one dose of solid SEDDS formulation was determined 
by using UV-VIS spectroscopy. 
Dissolution studies of solid SEDDS 
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The release of drug from solid SEDDS formulations and pure drug 
was determined using a US Pharmacopoeia Type II dissolution 
apparatus (Here same conditions and media applied as used for 
SEDDS. The dissolution media is phosphate buffer pH 6.8 (900ml), 
and temperature of the dissolution medium was maintained at 
370C operated at 50 rpm. 10ml sample was withdrawn at 
predetermined intervals 2, 5, 10, 15, 20, 30, 45 and 60 min and 
filtered through 0.45-μm pore size membrane filters. The 
concentrations were assayed spectrophotometrically at 250nm. 
Characterization of SEDDS 
Drug-Excipient compatibility studies by FTIR 
The IR spectra of pure drug, excipients and optimized formulations 
were recorded using FT-IR (Shimadzu 8400-S) with diffuse 
reflectance principle. Sample preparation involved, drying of 
potassium bromide (KBr), drug and excipients in the oven to get rid 
of any moisture content then mixing the sample with KBr by 
triturating in glass mortar. Finally preparing of pellet and placing in 
the sample holder. The spectrum was scanned over a frequency 
range 4000 ă 400 cm-1. [16]  
Differential scanning calorimetry (DSC) 
Differential Scanning Calorimetry (DSC) studies were carried out 
using DSC 60, having TA60 software, Shimadzu, Japan. 
Accurately weighed samples were placed on aluminium plate, 
sealed with aluminium lids and heated at a constant rate of 5ÀC 
/min, over a temperature range of 0 to 250ÀC [17]. 
Determination of droplet size 
The droplet size of the micro emulsions is determined by photon 
correlation spectroscopy (which analyses the fluctuations in light 
scattering due to Brownian motion of the particles) using a 
Zetasizer able to measure sizes between 2 nm and 5000 nm. Light 
scattering is monitored at 25ĈC at a 90Ĉ angle. 
Determination of zeta potential  
The emulsion stability is directly related to the magnitude of the 
surface charge. The zeta potential of the diluted SEDDS 
formulation was measured using a zeta meter system. Zeta-
potential of the resulting micro emulsion was determined using a 
Malvern Zetasizer [18].  
Micromeritic properties of Solid SEDDS 
Prepared S-SEDDS was evaluated for micromeritic properties such 
as angle of repose, bulk and tapped density, compressibility index 
and HausnerÊs ratio [19]. 
Drug entrapment efficiency of solid SEDDS 
The quantities of the drugs theoretically contained in the SEDDS 
were compared with the quantity actually obtained, from the drug 
content studies i.e. the quantity loaded into the SEDDS formulated 
[20].  
Scanning electron microscopy 
The surface and shape characteristics of pellets were determined 
by scanning electron microscopy (SEM) (HITACHI, S-3700N). 
Photographs were taken and recorded at suitable magnification. 
Stability studies 
The SEDDS formulations were put into empty hard gelatin 
capsules and subjected to stability studies at 25ĈC/60% relative 
humidity (RH), 30ĈC/65% RH, and 40ĈC/75% RH. Samples were 
charged in stability chambers (Thermolab, Mumbai, India) with 
humidity and temperature control. They were withdrawn at 
specified Accelerated conditions and 3months for long-term 
conditions. Drug content of the capsules was analyzed using a 
previously developed and validated stability-indicating UV method. 
In vivo bioavailability studies 
Twelve healthy Wister rats weighing 250 μ 20 g were used for this 
study. The protocol of animal study was approved by the 
institutional animal ethics committee. The Wister Rats were divided 
in to two groups at random and each group contains six animals. 
First group was administered with pure Valsartan made suspension 
with 0.5% methocel and second group was administered with solid 
SEDDS diluted in 0.5% methocel by oral route at an equivalent 
dose of 40 mg/kg body weight. About 500 øl of blood was 
withdrawn from retro orbital plexus at different time intervals such 
as 0.25, 0.50, 1.00, 1.50, 2.00, 2.50, 3.00, 4.00, 5.00, 6.00, 8.00 & 
24.00h. Blood samples were transferred into eppendorf tubes 
containing heparin in order to prevent blood clotting. The samples 
were centrifuged immediately at 4000 rpm and the plasma was 
stored in light-protected container at -20 0C till analysis. The 
concentration of Valsartan from plasma was measured by using 
reversed phase HPLC. The chromatographic system consisted of a 
C18 chromatographic column, Phenomenex (150 mm ï 4.6 mm ID) 
and a mobile phase consisting of acetonitrile-phosphate buffer 
(0.05 M) with pH 2.8 in the proportion of (40/60, v/v) at a flow rate 
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Figure 3: Solubility studies of Valsartan in Co-surfactants 
 
Construction of ternary phase diagram 
From the above chosen oils, surfactants and co-surfactants were 
taken in different ratios (Table 1) for the construction of ternary 
phase diagrams to know the emulsion and micro-emulsion 
domains such that at particular concentration of oil, surfactant and 
co-solvent ratios, a stable self-emulsifying formulation is formed. 
The Self emulsification process is affected on the concentration of 
Kolliphor HS-15 and PEG-400 and their ratio. The phase diagram 
representing that series I (3:1) and series II (2:1) showed a narrow 
microemulsifying domain (Figure 4). So the concentration of oil, 
surfactant and co-surfactant was selected in these domains for the 
study. From the phase diagrams, it was observed that self 
emulsifying region increased with increasing concentrations of 
surfactant or combination of surfactant and co-surfactant. 
Efficiency of self-emulsification was good when the surfactant 
concentration was increased. 
 
Figure 4: Ternary phase diagram of Capmul MCM, Kolliphor HS 15 
and PEG 400 
 
Visual observation and % Transmittance 
The clarity of microemulsions was checked by transparency, 
measured in terms of transmittance (%T). SEDDS forms o/w 
microemulsion since water is external phase. Some Formulations 
have % transmittance value greater than 99%.These results 
indicate the high clarity of microemulsion. In case of other systems 
%T values were about 97% suggesting less clarity of 
microemulsions. This may be due to greater particle size of the 
formulation. Due to higher particle size, oil globules may reduce the 
transparency of microemulsion and thereby values of %T. The 
results of %T are as shown in Table 3. 
From this liquid mixtures of Capmul MCM, Kolliphor HS 15  and 
PEG 400  of 1:9, 1:7 1:6 1:5 1:4 oil: Smix ratios belongs to 3:1 
Smix and 1:9, 1:8 1:7, 1:6 oil: Smix ratios belongs to 2:1 Smix 
shown highest % transmittance i.e. above 90%, therefore these 
ratios are suggested for high clarity of microemulsoin. In case of 
other ratios gave turbid solutions which are not suggesting for 
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Table 3: Visual observation and %Transmittance of different formulations 









     1:9       Transparent 99.56
     1:8       Slightly clear 89.99
     1:7       Transparent 99.50
     1:6       Transparent 92.24
     1:5       Transparent 99.89
     1:4       Transparent 97.12
     1:3        Turbid 70.02
     1:2        Turbid 57.52
     1:1        Turbid 20.99
     6:1        Turbid 18.78
     7:1        Turbid 10.34
     8:1        Turbid 15.89








     1:9        Transparent 96.98
     1:8        Transparent 96.22
     1:7        Transparent 97.09
     1:6        Transparent 95.53
     1:5        Slightly clear 87.99
     1:4        Slightly clear 88.84
     1:3        Slightly clear 54.89
     1:2        Slightly clear 48.97
     1:1        Turbid 28.72
     3:1        Turbid 14.99
     2:1             Turbid 25.52
 
Emulsification time 
The tendency of formation of emulsion was observed with this 
method. If the droplet spreads easily in water was judged as ÂgoodÊ  
and judged as ÂbadÊ  when there was milky or no emulsion or  
presence of oil droplets. Formulation F4 has % transmittance value 
greater than 99% (shown in table 3).These results indicate the high 
clarity of microemulsion. In case of other systems %T values were 
less than 99% suggesting less clarity of microemulsion. This may 
be due to greater particle size of the formulation. Due to higher 
particle size, oil globules may reduce the transparency of 
microemulsion and thereby values of %T. The results of %T are as 
shown in Table 4. 
 
Table 4: Emulsification time of SEDDS Formulations 
Smix (Surfactant: 
co-surfactant) 
Oil:Smix   Time       
(min) 




1:9 <1 Clear fibres, clear solution A 
1:7 <1 Clear fibres, clear solution A 
1:6 <1 Very Slight fibres, clear solution A/B
1:5 <1 Clear fibres, clear solution A 




1:9 <1 Very Slight fibres, clear solution A/B
1:8 <1 Slight fibres, clear solution A/B
1:7 <1 Slight fibres, clear solution A/B
1:6 <1 Very Slight fibres, clear solution A/B
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Preparation of Valsartan SEDDS 
SEDDS of Valsartan were prepared by using Capmul MCM (Oil), 
Kolliphor HS 15 (Surfactant) and PEG 400 (Co-surfactant). In the 
present investigation 9 formulations were prepared and their 
complete composition is shown in Table 1.  All the prepared 
SEDDS were found to be clear.  
Freeze thaw method 
In thermodynamic stability study, no phase separation and no 
change of temperature variations on prepared formulations were 
observed. There was no change in the visual description of 
samples after centrifugation freeze-thaw cycles.  
Drug content of SEDDS 
Actual drug content of all 9 formulations are shown in Table 5. The 
drug content of the prepared SEDDS was found to be in the range 
of 91.50 ă 98.11 %. Maximum % drug content i.e. 98.11% was 













In Vitro Dissolution Studies of SEDDS 
The results of in vitro dissolution comparisons of SEDDS 
formulations are summarized in Table 6. The faster and highest 
drug dissolution from SEDDS may be attributed to the fact that in 
this formulation, the drug is a solubilized form and upon exposure 
to dissolution medium results in small droplet that can dissolve 
rapidly in the dissolution medium. The release from SEDDS 
formulation F4 was highest (97.34) faster than other SEDDS 
formulations and pure drug substance indicating influence of 
droplet size on the rate of drug dissolution. 
Table 6: Dissolution profiles of various formulations                                                                                                      
 
Time (min) 
          Dissolution media ă Phosphate buffer pH 6.8 (% drug release)      
                                         Formulation Code 
Pure drug F1 F2 F3 F4 F5 F6 F7 F8 F9 
0 0 0 0 0 0 0 0 0 0 0 
2 2.29 28.19 14.78 42.01 39.53 25.12 21.76 19.92 29.7 15.33 
5 10.10 57.71 66.80 56.75 78.10 46.37 50.18 42.42 42.2 45.96 
10 17.90 69.19 74.47 66.62 85.68 52.97 63.91 53.81 63.9 68.05 
    15 21.12 71.72 79.39 74.63 90.50 61.66 68.52 59.91 71.8 70.76 
20 23.41 78.82 82.48 79.92 92.61 75.54 72.39 67.66 79.9 81.82 
25 30.70 83.37 87.58 82.79 95.28 80.05 79.86 79.95 81.1 85.27 
30 35.81 90.50 91.62 86.34 96.33 87.06 83.84 81.65 84.8 89.07 
45 37.19 91.21 91.99 86.88 96.33 87.34 84.31 82.20 85.0 89.43 
60 43.60 91.43 92.04 87.11 97.34 87.61 84.56 82.66 85.3 89.71 
 
Selection of optimized formulation  
When compared to % transmittance, emulsification test and in vitro 
drug release studies for all formulations, F4 formulation was found 
to be best and optimized formulation and further characterized for 
other studies.  
 
              Formulation 
                   Code         Assay (%) 
                   F1            96.43
                   F2            96.16
                   F3            91.50
                   F4            98.11
                   F5            94.84
                   F6            93.76
                   F7            94.98
                   F8            92.64
                   F9            95.31
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  Figure 5: Adsorption studies of Valsartan with different adsorbents 
Oil adsorption study 
Oil adsorption study was performed for Valsartan by using different 
adsorbents and results are depicted in Figure 5. Neusilin US2 
showed higher oil adsorption capacity when compared to other 
adsorbents. From oil adsorption study Neusilin US2 was used for 
the preparation of Solid SEDDS from optimized SEDDS 
formulation (F4). 
Conversion of SEDDS to Solid SEDDS 
On the basis of faster and complete dissolution rate, formulation F4 
was selected as optimized formulation and this formulation was 
converted in to solid SEDDS by adding required quantity of 
Neusilin US2 as adsorbing agent.  
Micromeretic properties of Valsartan solid 
SEDDS 
The micromeretic properties angle of repose, LBD, TBD, CarrÊs 
index and HausnerÊs ratio of the solid SEDDS was found to be 
28.31, 0.22, 0.25, 13.30 and 1.16 respectively, which shows good 
flow properties of the powdered blend.  
Drug content of solid SEDDS 
The drug content of solid SEDDS was carried out. The % assay of 
the solid SEDDS was found to be 98.31%. 
Drug entrapment efficiency 
The dug entrapment efficiency of solid SEDDS was carried out. 
The results of drug entrapment efficiency of solid SEDDS 
formulation was found to be 92.57% 
Dissolution Studies of Valsartan pure drug Solid 
and Liquid SEDDS and Innovator product 
(Valzaar 40mg) 
The release of Valsartan from solid, liquid SEDDS formulations, 
pure drug and innovator product - Valsartan 40mg tablets (Valzaar 
40mg) was determined. The concentrations were assayed 
spectrophotometrically at 250nm. Comparative dissolution profiles 
of solid and liquid SEDDS formulation (F4) with pure drug and 
innovator product are summarized in Table 7. Solid and liquid 
SEDDS have shown better release profiles when compared with 
the pure drug and the innovator product. 
 










                 Table 7: Comparative results of drug release from SEDDS, Solid SEDDS, Pure drug and Innovator product (Valzaar 40mg) 
 
 
Particle size analysis for SEDDS 
Droplet size of Valsartan emulsion decreased with reducing the oil 
content in SEDDS (Figure 6). The smaller the droplet size, the 
larger the interfacial surface area will be provided for drug 
absorption. The size of F4 was found to be below range of 71.1 nm 
which indicated that formulation F6 was SEDDS. The 
Polydispersity index of the optimized Valsartan formulation (F4) 
was found to be 0.064. 
 
 
                 Figure 6: Particle size analysis of optimized formulation 
 
Zeta potential 
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The optimized formulation F4 was shown very low polydispersive 
index and low viscosity.  
The zeta potential of the optimized Valsartan formulation was 
found to be very low i.e.,         -40.6Mv. Hence, the formulation 
rapidly formed emulsion and remained stable for longer time 
(Figure 7) 
 
Figure 7: Zeta potential of the optimized formulation 
 
Drug excipient compatibility studies 
FTIR Studies 
The FTIR spectra of pure Valsartan displayed bands at 3419.9 cm-
1 due to N-H stretch, at 2962.76 cm-1  due to C=N stretching, at 
1732.13 cm-1  due to Carboxylate stretching. The spectra also 
showed bands at 1631.83 cm-1 due to C=O bending at 1107.18 
due to C-N bonding (Figure 8). The FTIR spectrum of Valsartan 
SEDDS exhibited characteristic bands consistent with the 
molecular structure of Valsartan which indicated that no chemical 
interaction occurred between the drug and excipients used in the 
formulation (Figure 9). 
 
 
Figure 8: FTIR Spectrum of Valsartan pure drug  
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Figure 9: FTIR Spectrum of optimized formulation of Valsartan liquid SEDDS 
 
Drug excipient interactions by DSC studies 
Differential Scanning Calorimetry (DSC) was performed on pure 
drug, excipients and optimized formulation. DSC results revealed 
that the pure drug Valsartan showed a melting point at 116ÀC, and 
optimized SEDDS formulation at 119 ÀC. There was no 
considerable change observed in melting endotherm of drug in 
optimized formulation. It indicates that there was no interaction 
between drug and other excipients used in the formulation (Figure 
10).  
 
Figure 10: DSC thermograms of pure drug and optimized SEDDS 
(F4) formulation              
Scanning electron microscopy  
Micrographs of Solid SEDDS shows Liquid SEDDS adsorbed onto 
the surface of Neusilin US2 particles. Since the formulation 
process involved facilitating adsorption through physical mixing, 
partially covered Neusilin US2 is also visible in the field of vision. 
Crystalline structures characteristic of Valsartan are not seen in 
solid SEDDS micrographs suggesting that the drug is present in a 
completely dissolved state in the Solid SEDDS. Figure 11(i) & (ii) 
represents the morphology of solid SEDDS. This indicates that 





Figure 11(i) & (ii): Scanning Electron Microscopy of Solid SEDDS 
 
Stability studies 
The Valsartan SEDDS are put into hard gelatin capsules as the 
final dosage form. The developed formulation was subjected to 
stability studies to evaluate its stability and the integrity of the 
dosage form. There was no significant change in the drug content, 
drug release. It was also seen that the formulation was compatible 
with the hard gelatin capsule shells, as there was no sign of 
capsule shell deformation. There was no significant change in the 
appearance, or microemulsifying property. Thus, these studies 
confirmed that the formulation was stable and its compatibility with 
hard gelatin capsules. 
Bioavailability studies 
Table 8: Pharmacokinetic Parameters of Valsartan solid SEDDS formulation and pure drug (n = 6) 
Pharmacokinetic Parameters Valsartan Pure drug Valsartan - solid SEDDS 
C max (øg/ml) 0.416 0.928
AUC 0-t (øg h/ml) 3.62 5.94
AUC 0-inf (øg h/ml) 3.85 6.05
T max (h) 2.70 3.18 
t 1/2 (h) 5.32 6.52 
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                  Figure 12: Plasma concentration profiles of Valsartan solid 
SEDDS and pure drug 
Pharmacokinetic studies were carried out in healthy Wister rats for 
test formulation and reference pure drug and the results were 
depicted in Table 8. The comparison of plasma drug concentration 
of test formulation and reference pure drug was shown in Figure 
12. As can be seen from the above table Cmax of the solid SEDDS 
0.928 øg/ ml was significant (p<0.05) as compared to the pure drug 
suspension formulation 0.416 øg/ ml. Tmax of  both solid SEDDS 
formulation and pure drug suspension was 3.18 and 2.70 h, 
respectively. AUC is an important parameter in evaluating 
bioavailability of drug from dosage form, as it represents the total 
integrated area under the blood concentration time profile and 
represents the total amount of drug reaching the systemic 
circulation after oral administration. AUC0-¥ infinity for solid SEDDS 
formulation was higher 6.05 øg h/ml than the pure drug suspension 
formulation 3.85 øg h/ml. The relative bioavailability of the solid 
SMEDDS formulation was 1.6-fold higher compared to the pure 
suspension. Therefore, drug delivery using solid SMEDDS is a 
promising approach for the effective absorption and rapid onset of 
action after oral administration of this drug and for improvement of 
its oral bioavailability.  
Summary and conclusion 
Systematic efforts were made to prepare nine formulations of 
valsartan SEDDS by using different polymers like Capmul MCM, 
Castor oil, Capryol -90, Vitamin E TPGS, Kolliphor HS 15, Kolliphor 
RH 40, Kolliphor ELP, Gelucire 44/14, Kolliphor EL Labrasol, 
Lauroglycol, PEG 400, PEG 600, Propylene glycol. From this study 
it was concluded that, prepared liquid SEDDS was 
thermodynamically stable with good self emulsification efficiency 
and having globule size in nanometric range which may be 
physiologically stable. On the basis of different evaluation 
parameters F4 was found to be optimized formulatin. Study also 
concluded that, S-SEDDS of Valsartan prepared with optimized 
SEDDS (F4) using adsorbing agent Neusilin US2 by adsorption 
technique have good flow property and drug content. SSEDDS 
formed clear micro emulsion with micrometric size. Results of SEM 
demonstrate that spherical S-SEDDS can be obtained without 
agglomeration. In-vitro drug release of S-SEDDS was much higher 
than that of pure Valsartan, SEDDS and marketed formulation. 
Hence it was concluded that S-SEDDS can be efficiently 
formulated by adsorption technique using Neusilin US2 as solid 
carrier to enhance dissolution rate of poorly soluble drug such as 
Valsartan. The oral bioavailability study of Valsartan solid 
SMEDDS showed improvement by a factor of 1.6 compared to the 
suspension in rats. Thus solid SMEDDS may be used for 
improvement of oral bioavailability of drugs with poor water 
solubility and low oral bioavailability. 
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